Why the study?
Over-prescribing of PPIs is common in older patients, and while deprescribing services decrease inappropriate utilization, their cost-effectiveness from the perspective of Hong Kong public healthcare providers remained to be examined.
Does a PPI deprescribing service reduce direct medical costs and QALY loss in older PPI-users compared to usual care?
Does a PPI deprescribing service reduce direct medical costs and QALY loss in older PPI-users compared to usual care?
A PPI deprescribing service is highly cost-effective for older patients in Hong Kong, reducing costs and saving QALYs.
Answers are grounded in this paper and cite their sources.
PPI deprescribing may be cost-effective in older adults; leaves open need for prospective trials before routine adoption.
Over-prescribing of proton-pump inhibitors (PPIs) is widely observed in older patients. Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. We aimed to examine the cost-effectiveness of PPI deprescribing service from the perspective of Hong Kong public healthcare provider. A decision-analytic model was constructed to examine the clinical and economic outcomes of PPI deprescribing service (deprescribing group) and usual care (UC group) in a hypothetical cohort of older PPI-users aged ≥65 years in the ambulatory care setting. The model inputs were retrieved from literature and public data. The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. Primary model outcomes were direct medical cost and quality-adjusted life-years (QALYs) loss. In base-case analysis, the deprescribing service (versus UC) reduced total direct medical cost by USD235 and saved 0.0249 QALY per PPI user evaluated. The base-case results were robust to variation of all model inputs in one-way sensitivity analysis. In probabilistic sensitivity analysis, the deprescribing group was accepted as cost-effective (versus the UC group) in 100% of the 10,000 Monte Carlo simulations. In conclusion, the PPI deprescribing service saved QALYs and reduced total direct medical cost in older PPIs users, and showed a high probability to be accepted as the cost-effective option from the perspective of public healthcare provider in Hong Kong.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: